BSTG:OTC-Biostage Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 3.10

Change

+0.10 (+3.33)%

Market Cap

USD 0.03B

Volume

1.68K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-2.99 (-2.76%)

USD246.77B 36.17 3.94
CSLLY CSL Limited

+0.95 (+0.85%)

USD101.34B 42.69 28.82
CMXHF CSL Limited

+0.82 (+0.37%)

USD100.28B 42.24 28.82
WXXWY WuXi Biologics (Cayman) Inc

-0.44 (-1.44%)

USD64.88B 151.29 17.94
WXIBF WuXi Biologics (Cayman) Inc

N/A

USD61.75B 140.10 18.20
GNMSF Genmab A/S

-17.34 (-3.71%)

USD30.53B 78.46 9.04
UCBJF UCB SA

N/A

USD22.26B 20.68 15.88
UCBJY UCB SA

+0.03 (+0.05%)

USD22.19B 20.81 15.42
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.21B 10.62 1.10
SBMFF Sino Biopharmaceutical Limited

N/A

USD14.52B 9.30 1.10

ETFs Containing BSTG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 148.00% 89% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.00% 89% B+ 87% B+
Trailing 12 Months  
Capital Gain 127.94% 83% B 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 127.94% 82% B- 81% B-
Trailing 5 Years  
Capital Gain 244.44% 86% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 244.44% 85% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 328.30% 87% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 328.30% 87% B+ 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 852.59% 17% F 11% F
Risk Adjusted Return 38.51% 68% D+ 60% D-
Market Capitalization 0.03B 56% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 40.59 14% F 5% F
Price / Cash Flow Ratio -7.19 63% D 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -613.78% 11% F 3% F
Return on Invested Capital -406.80% 6% F 3% F
Return on Assets -179.27% 20% F 7% F
Debt to Equity Ratio 10.67% 35% F 66% D
Technical Ratios  
Short Ratio 3.35 24% F 21% F
Short Percent 6.77% 24% F 21% F
Beta -0.16 84% B 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.